Inventor · disambiguated record
John Sapienza
Also filed as: SAPIENZA JOHN · SAPIENZA JOHN J · SAPIENZA JOHN JOSEPH
38 granted patents·13 pending applications·671 citations·filing 2001–2024
98Inventor score
Files withSIGNAL PHARM LLC20CELGENE CORP17PERRIN-NINKOVIC SOPHIE3BAHMANYAR SOGOLE2BHAGWAT SHRIPAD S2
Top patents by PatentIndex Score
51 records- 0198US7981893B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jul 19, 2011·90 cites·10 claims
- 0296US11634407B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Apr 25, 2023·5 cites·66 claims
- 0396US11149007B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Oct 19, 2021·14 cites·41 claims
- 0496US8492381B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Jul 23, 2013·44 cites·21 claims
- 0596US8110578B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2009·Granted Feb 7, 2012·67 cites·28 claims
- 0695US8383634B2Methods of treatment using heteroaryl compounds and compositions thereofSIGNAL PHARM LLC·Filed 2011·Granted Feb 26, 2013·46 cites·4 claims
- 0795US8372976B2Methods of treatment comprising the administration of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2011·Granted Feb 12, 2013·40 cites·1 claims
- 0895US7968556B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jun 28, 2011·41 cites·3 claims
- 0995US7723340B2Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2006·Granted May 25, 2010·46 cites·51 claims
- 1094US11325889B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted May 10, 2022·11 cites·35 claims
- 1193US11873283B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 16, 2024·2 cites·34 claims
- 1293US11739075B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Aug 29, 2023·3 cites·17 claims
- 1393US11560371B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 24, 2023·3 cites·18 claims
- 1493US8507492B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Aug 13, 2013·22 cites·20 claims
- 1593US6897231B2Indazole derivatives as JNK inhibitors and compositions and methods related theretoSIGNAL PHARM INC·Filed 2001·Granted May 24, 2005·62 cites·26 claims
- 1691US8569494B2Methods of synthesis and purification of heteroaryl compoundsHARRIS ROY L·Filed 2010·Granted Oct 29, 2013·27 cites·23 claims
- 1790US10227325B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2018·Granted Mar 12, 2019·6 cites·18 claims
- 1889US9556126B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2014·Granted Jan 31, 2017·10 cites·32 claims
- 1988US9938254B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2017·Granted Apr 10, 2018·5 cites·33 claims
- 2088US9771371B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2015·Granted Sep 26, 2017·4 cites·6 claims
- 2188US8101588B2Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewithALBERS RONALD J·Filed 2009·Granted Jan 24, 2012·22 cites·29 claims
- 2287US8299056B2Aminotriazolopyridines, compositions thereof, and methods of treatment therewithBAHMANYAR SOGOLE·Filed 2009·Granted Oct 30, 2012·22 cites·31 claims
- 2386US9156798B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Oct 13, 2015·5 cites·30 claims
- 2486US7220771B2Methods of using indazole derivatives as JNK inhibitorsSIGNAL PHARM LLC·Filed 2003·Granted May 22, 2007·22 cites·4 claims
- 2584US9079900B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2014·Granted Jul 14, 2015·5 cites·27 claims
- 2684US8907087B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Granted Dec 9, 2014·4 cites·11 claims
- 2783US7211594B2Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewithSIGNAL PHARM LLC·Filed 2003·Granted May 1, 2007·23 cites·6 claims
- 2883US7208513B2Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewithSIGNAL PHARM LLC·Filed 2004·Granted Apr 24, 2007·16 cites·12 claims
- 2981US12404241B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Sep 2, 2025·0 cites·16 claims
- 3080US10167290B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2017·Granted Jan 1, 2019·1 cites·5 claims
- 3180US2023119470A1PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAYSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 3279US9783505B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Oct 10, 2017·2 cites·29 claims
- 3378US10618883B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2019·Granted Apr 14, 2020·1 cites·15 claims
- 3478US2025188056A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 3576US12103920B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Oct 1, 2024·0 cites·15 claims
- 3674US11292796B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2020·Granted Apr 5, 2022·0 cites·5 claims
- 3772US12227490B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Feb 18, 2025·0 cites·18 claims
- 3872US10683298B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Jun 16, 2020·0 cites·8 claims
- 3970US9193692B2Halogen substituted pyrazines as intermediates of mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2014·Granted Nov 24, 2015·0 cites·14 claims
- 4069US11365184B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2020·Granted Jun 21, 2022·0 cites·12 claims
- 4164US2024067632A1WEE1 Degrading Compounds and Uses ThereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 4261US2025100995A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 4360US2009312320A1Methods of treatment comprising the administration of haloaryl substituted aminopurines or compositions thereofSIGNAL PHARM LLC·Filed 2009·Application pending·0 cites
- 4459US2024368118A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 4559US2024374591A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 4657US2024158370A1CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDSINNOVO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4753US2009099178A1Indazole compounds and methods of use thereofBHAGWAT SHRIPAD S·Filed 2008·Application pending·0 cites
- 4848US2006004043A1Indazole compounds and methods of use thereofBHAGWAT SHRIPAD S·Filed 2004·Application pending·0 cites
- 4948US2005009876A1Indazole compounds, compositions thereof and methods of treatment therewithFiled 2003·Application pending·0 cites
- 5046US2008242694A1Amino-substituted heterocycles, compositions thereof, and methods of treatment therewithD SIDOCKY NEIL R·Filed 2007·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →